| Nov 16 |
Jaguar Health Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
|
| Nov 15 |
Jaguar Health, Inc. (JAGX) Q3 2024 Earnings Call Transcript
|
| Nov 14 |
Jaguar Health Inc (JAGX) Q3 2024 Earnings Call Highlights: Revenue Growth and Strategic ...
|
| Nov 13 |
Jaguar Health GAAP EPS of -$1.05, revenue of $3.11M
|
| Nov 13 |
Jaguar Health Reports Third Quarter 2024 Financial Results
|
| Nov 13 |
Earnings Scheduled For November 13, 2024
|
| Nov 6 |
FDA Approves Renewal of Canalevia-CA1, Jaguar Health's Drug for Chemotherapy-Induced Diarrhea in Dogs
|
| Nov 4 |
Abstract Describing Significant Results of Crofelemer for Cancer Therapy-Related Diarrhea in Breast Cancer Patients Accepted for Presentation at San Antonio Breast Cancer Symposium (SABCS)
|
| Oct 29 |
Significant Positive Results with Jaguar Health's Crofelemer for Chronic Refractory Diarrhea in IBS-D, Presented at American College of Gastroenterology Annual Meeting
|
| Oct 16 |
Jaguar Health Launches FDA-Approved Oral Mucositis Prescription Product Gelclair in the U.S.
|
